Email this article Press release
- Authors: - -
- Issue: Vol 16, No 4 (2014)
- Pages: 5-6
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26948
- ID: 26948
Cite item
Full Text
Abstract
Perjeta™ (pertuzumab) in combination with Herceptin® (trastuzumab) and docetaxel increases in life expectancy of patients with HER2-positive metastatic breast cancer (mBC) by 15,7 months compared with standard regimen Herceptin/docetaxel. The data from the phase III CLEOPATRA study.
Full Text
##article.viewOnOriginalSite##References
- Swain S et al. Final overall survival (OS) analysis from the CLEOPATRA study of first - line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology 2014. Abstr. 350O_PR.
- F. Hoffmann-La Roche. ClinicalTrials.gov NCT00567190. National Library of Medicine; http://clinicaltrials.gov/ct2/show/NCT00567190
- Swain S et al. Confirmatory overall survival analysis of CLEOPATRA: A randomized, double - blind, placebo - controlled Phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first - line metastatic breast cancer. Poster presentation at the 2012 CTRC- AACR San Antonio Breast Cancer Symposium. Abstr. P5-18-26.
- Wolff A.C et al. Arch Pathol Lab Med 2007; 131: 18-34.
- Dawood S et al. J Clin Oncol 2010; 28: 92.
